Clinical Trial

A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study

Study acronym: CRIMI
Unknown Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 12, 2022 (before its estimated July 2024 completion). Its status may not reflect the trial's current state.
Summary
A multicenter Phase 1b/2, two stage, open label study of MMC/Capecitabine ChRT combined with nivolumab monotherapy or nivolumab and ipilimumab combination therapy in adult (\>18 years) subjects with non-metastatic muscle invasive bladder cancer that qualify for ChRT with curative intent.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-09
Trial Details
NCT Number NCT03844256
Lead Sponsor Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Collaborators: Bristol-Myers Squibb
Conditions Urinary Bladder Cancer, Invasive Bladder Cancer
Enrollment 50 participants
Start Date 2019-01-07
Primary Completion 2024-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2022-08-12